Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study-Reference-Cited by-同舟云学术

Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

Published:2018-08-02 Issue:1 Volume:18 Page:
ISSN:1471-244X
Container-title:BMC Psychiatry
language:en
Short-container-title:BMC Psychiatry

Author:

Mamakou Vasiliki^ORCID,Hackinger Sophie,Zengini Eleni,Tsompanaki Evgenia,Marouli Eirini,Serafetinidis Ioannis,Prins Bram,Karabela Athina,Glezou Eirini,Southam Lorraine,Rayner Nigel W.,Kuchenbaecker Karoline,Lamnissou Klea,Kontaxakis Vassilis,Dedoussis George,Gonidakis Fragiskos,Thanopoulou Anastasia,Tentolouris Nikolaos,Zeggini Eleftheria

Funder

Wellcome Trust

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health

Link

http://link.springer.com/content/pdf/10.1186/s12888-018-1826-4.pdf

Reference58 articles.

1. Suvisaari J, Keinanen J, Eskelinen S, Mantere O. Diabetes and Schizophrenia. Curr Diab Rep. 2016;16(2):16. https://doi.org/10.1007/s11892-015-0704-4 .

2. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39(2):295–305. https://doi.org/10.1093/schbul/sbs082 .

3. Collaboration NCDRF. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–30. https://doi.org/10.1016/S0140-6736(16)00618-8 .